Core Insights - The U.S. equity markets reached new all-time highs in Q4 2025, with the S&P 500 Index rising 2.66% and the Bloomberg U.S. Aggregate Bond Index increasing by 1.10% [1] - The Aristotle Growth Equity Fund (Class I-2) returned 0.95%, underperforming the Russell 1000 Growth Index's 1.12% due to poor security selection in the information technology and consumer discretionary sectors [1] Company Performance - UnitedHealth Group Incorporated (NYSE:UNH) closed at $284.20 per share on February 25, 2026, with a one-month return of -2.77% and a 52-week loss of 39.35% [2] - The company has a market capitalization of $257.439 billion [2] Investment Decisions - The fund sold UnitedHealth Group due to lowered guidance, increased utilization, and a higher-than-expected medical cost ratio, which negatively impacted earnings [3] - The CEO and CFO of UnitedHealth Group were recently replaced, and while the stock has rebounded over 50% from early August lows, it is believed to take several years for earnings to return to prior levels [3] Hedge Fund Interest - UnitedHealth Group is ranked 18th among the 30 Most Popular Stocks Among Hedge Funds, with 145 hedge fund portfolios holding the stock at the end of Q4, up from 140 in the previous quarter [4] - Despite the potential of UnitedHealth Group as an investment, the company is viewed as having less upside compared to certain AI stocks [4]

Core Viewpoint - Elevance Health Inc. (NYSE:ELV) is considered one of the most undervalued large-cap stocks currently available for investment, despite recent adjustments in price targets by various analysts [1]. Analyst Ratings and Price Targets - Barclays has lowered its price target for Elevance Health to $393 from $404 while maintaining an Overweight rating [1]. - Guggenheim analyst Jason Cassorla has also reduced the price target to $396 from $414, keeping a Buy rating based on recalibrated 2026 estimates following the company's Q4 2025 report [1]. - Deutsche Bank raised its price target to $332 from $320, maintaining a Hold rating, suggesting that the company's 2026 outlook may represent a floor [2]. - UBS has lowered its price target to $400 from $425 while maintaining a Buy rating [3]. Company Overview - Elevance Health Inc. operates as a health benefits company in the US, with four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other [3].

Core Insights - Elevance Health Inc. (NYSE:ELV) is identified as a potentially undervalued stock within the S&P 500, with recent price target increases from analysts indicating positive sentiment towards the company [1][2]. Analyst Ratings and Price Targets - Mizuho analyst Ann Hynes raised the price target for Elevance Health to $413 from $400, maintaining an Outperform rating, while also noting a slowdown in healthcare utilization growth, suggesting a peak in recent healthcare demand [1][3]. - Wells Fargo increased its price target for Elevance Health to $424 from $403, maintaining an Overweight rating, with a focus on confidence in Medicare Advantage amidst uncertainties in Medicaid and health insurance exchanges [2]. Market Environment and Future Outlook - Mizuho anticipates a challenging environment for hospitals in 2026 as post-COVID tailwinds fade and legislative risks emerge, indicating potential headwinds for the healthcare sector [3]. - The ongoing debate regarding healthcare distributors revolves around whether performance will be influenced more by earnings revisions or valuation multiples, highlighting the complexities in the market [3]. Company Overview - Elevance Health operates as a health benefits company in the US, with four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other, indicating a diversified business model [4].

Group 1 - Elevance Health, Inc. (NYSE:ELV) is considered a cheap healthcare stock with a median price target of $394, indicating an upside potential of 19.12% [1] - TD Cowen raised the price target for Elevance Health to $400 from $380, maintaining a 'Buy' rating and highlighting it as their "Best Idea for 2026" [2] - Mizuho reduced its price target for Elevance Health to $400 from $420 while keeping an 'Outperform' rating, also lowering earnings guidance for 2026 and 2027 due to challenges in Carelon [3] Group 2 - Elevance Health operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other, and aims to simplify the healthcare system [4]

Core Insights - Elevance Health, Inc. operates as a health benefits company with a market cap of $74.7 billion, supporting consumers and communities throughout their healthcare journey [1][2] Company Overview - Elevance employs over 100,000 associates and serves millions, addressing a full range of health needs through an integrated approach and a digital health platform [2] Stock Performance - Elevance's stock has dropped 26.2% from its 52-week high of $458.75 on April 8, but has gained 9.2% over the past three months, outperforming the Nasdaq Composite's 7.8% gains during the same period [3] - Year-to-date, Elevance's stock has declined 8.2% and 15.8% over the past 52 weeks, while the Nasdaq has surged 20.2% in 2025 and 21.1% over the past year [4] Financial Results - Despite better-than-expected Q3 results, Elevance's stock dropped 1.2% following the earnings release on October 21. The company reported a 12% year-over-year increase in topline revenue to $50 billion, exceeding expectations by 1.2% [5] - Adjusted EPS for the quarter was $6.03, a 29.9% year-over-year decline, but surpassed consensus estimates by 21.1% [5] Peer Comparison - Elevance has underperformed compared to The Cigna Group, which saw a marginal 80 basis points increase year-to-date, but performed slightly better than Cigna's 16.9% drop over the past 52 weeks [6]

Core Insights - Progyny, Inc. reported revenue of $313.3 million for Q3 2025, reflecting a 9.3% growth compared to Q3 2024, driven by an increase in clients and covered lives [1][6] - The company raised its full-year guidance due to strong member engagement and performance in the selling season, which added over 80 new clients and approximately 900,000 new lives [1][18] - Progyny generated a record $156 million in operating cash flow over the first nine months of 2025 and authorized a share repurchase program of up to $200 million [1][3] Financial Performance - Revenue for Q3 2025 was $313.3 million, up from $286.6 million in Q3 2024, marking a 9.3% increase [4][6] - Gross profit increased to $72.8 million, a 23% rise from $59.2 million in the prior year, with a gross margin of 23.2% compared to 20.7% [7][4] - Net income for Q3 2025 was $13.9 million, or $0.15 per diluted share, up from $10.4 million, or $0.11 per diluted share, in Q3 2024 [8][4] - Adjusted EBITDA reached $55.0 million, an 18% increase from $46.5 million in Q3 2024, with an adjusted EBITDA margin of 17.5% [9][4] Client and Market Engagement - The recent selling season resulted in commitments from over 80 new clients, representing approximately 900,000 new lives, with nearly 100% retention of existing clients [3][20] - Progyny's new programs, including pregnancy-postpartum and menopause services, are gaining traction, with over 2.7 million lives expected to access these solutions in 2026 [3][20] - The company had 553 fertility and family building clients as of September 30, 2025, compared to 468 clients a year earlier [12] Cash Flow and Financial Position - Net cash provided by operating activities in Q3 2025 was $50.7 million, compared to $44.5 million in Q3 2024 [10] - As of September 30, 2025, the company had total working capital of approximately $411.5 million and no debt, with cash and cash equivalents totaling $345.2 million [11] - The company entered into a revolving credit facility of up to $200 million, which remains undrawn [11] Financial Outlook - For the full year 2025, revenue is projected to be between $1.263 billion and $1.278 billion, reflecting growth of 8.2% to 9.5% [21] - Net income for the full year is expected to be between $58.5 million and $61.5 million, or $0.65 to $0.68 per diluted share [21] - The fourth quarter revenue is projected to be between $292.7 million and $307.7 million, with a potential increase of 11.5% to 17.2% when excluding revenue from a large client that did not renew its services agreement [21]

Core Insights - Elevance Health, Inc. (NYSE:ELV) is highlighted as one of the stocks with the lowest P/E ratios on the NYSE [1] - Cantor Fitzgerald has reaffirmed its Overweight rating and set a price target of $400 for Elevance Health, indicating confidence in the company's future performance [2] - The company’s weighted-average estimate for 2026 Marketplace rates is only about 40 basis points away from proposed rates, with most initial state authorizations aligning closely with payor plans [2] - Less than 25% of members currently have final rates, and political factors may still influence outcomes related to the CMS Marketplace Integrity & Affordability Final Rule [3] - Elevance Health has reiterated its 2025 earnings outlook, projecting a benefit expense ratio near 90% and earnings of $24.10 per diluted share, with an adjusted basis projection of approximately $30.00 [4] Business Segments - Elevance Health operates through four main business segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other [4]

Core Insights - Elevance Health, Inc. is facing challenges from rising medical costs, slower Medicaid recovery, and increased utilization, leading to a reduced outlook for 2025 [1][5] - The company reported a significant increase in benefits expenses and cost of products sold in the first half of the year [1] Financial Performance - Benefits expense surged nearly 18% to over $72 billion, while cost of products sold increased almost 19% to $10.3 billion [1] - The second-quarter benefit expense ratio reached 88.9%, up 260 basis points year over year, with a projected full-year ratio of about 90% compared to 88.5% in 2024 [2][9] Membership and Growth - Commercial individual memberships rose 9.7% in the first half of 2025, following a 25.6% increase in 2024, indicating strong growth in the commercial segment [3][9] - Carelon's revenue is expected to grow nearly 30% in 2025, driven by a 60% surge in Carelon Services [4][9] Competitive Landscape - Other companies in the health benefits space, such as UnitedHealth Group and Centene Corporation, are also experiencing pressure from rising medical costs [6] - UnitedHealth's medical care ratio deteriorated to 89.4%, while Centene's health benefits ratio reached 93%, indicating industry-wide challenges [7] Valuation and Estimates - Elevance's shares have declined 20.7% year-to-date, compared to a 3.9% decline in the industry [8] - The forward price-to-earnings ratio for Elevance is 9.19, significantly lower than the industry average of 14.57, with a Zacks Consensus Estimate for 2025 earnings at $30.59 per share, reflecting a 7.4% decline from the previous year [10][11]

Core Viewpoint - Elevance Health, Inc. is trading at a discount with a forward 12-month P/E ratio of 10.35X, below its five-year median of 13.46X and the industry average of 13.86X, indicating attractive valuation compared to peers [1][2] Group 1: Growth Drivers - Elevance is positioned for sustained growth through strategic initiatives in its commercial and government segments, with commercial memberships growing 4.6% and 1% year-over-year in 2024, and a notable 14.2% increase in its Individual Commercial business in Q1 2025 [4][5] - The company has streamlined its government business by exiting underperforming markets, enhancing efficiency and potential for growth in Medicare Advantage in underpenetrated states [5] - Elevance's Return on Invested Capital stands at 9.94%, significantly above the industry average of 5.79%, showcasing superior capital deployment capabilities [6] Group 2: Shareholder Returns - The company is committed to returning capital to shareholders, having repurchased $880 million worth of shares in Q1 2025, with $8.4 billion remaining under its buyback authorization, and a dividend yield of 1.82%, exceeding the industry average of 1.40% [7] Group 3: Market Performance - Despite broader market challenges, Elevance shares have gained 1.9% year-to-date, outperforming both the industry and the S&P 500, while peers UnitedHealth and Humana have experienced declines [8] Group 4: Financial Estimates - The Zacks Consensus Estimate for Elevance's EPS indicates a 4.2% increase for 2025 and a 13.8% increase for 2026, with revenue estimates suggesting an 11.2% increase for 2025 and a 7.1% increase for 2026 [11] Group 5: Challenges and Risks - Elevance faces challenges including a decline in Medicaid and Medicare Supplement membership, which could lead to overall membership losses and reduced revenues [12] - Rising medical costs are a significant concern, with the benefit expense ratio increasing from 87% in 2023 to an estimated 88.7% in 2025, indicating pressure on earnings [13] - Regulatory uncertainties, particularly related to the Pharmacy Benefit Management industry, pose additional risks for Elevance [14]